BUZZ-SpringWorks rises as FDA grants priority review to genetic disorder drug

Reuters08-28

** Shares of SpringWorks Therapeutics rise 2.5% to $42.1

** Co says the U.S. Food and Drug Administration has granted Priority Review to its application seeking approval for its experimental drug to treat NF1-PN in adult and pediatric patients

** NF1-PN is a rare genetic disorder characterized by changes in skin coloring and the growth of tumors along nerves in the skin, brain and other parts of the body

** FDA is set to make a decision on the drug, mirdametinib, by February 28, 2025 - SWTX

** FDA is not currently planning to hold an advisory committee meeting to discuss the application - SWTX

** Including session moves, stock had risen 13.3% YTD

(Reporting by Mariam Sunny in Bengaluru)

((Mariam.ESunny@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment